Real-World, Data-Driven Strategies to Improve Outcomes in Cirrhosis and Metabolic Disease

Examine the complexities of translating scientific research and real-world data into actionable clinical workflows in the care of patients with cirrhosis and coexisting metabolic disease across the transplant continuum in this educational session. As metabolic comorbidities increasingly shape risk regardless of liver disease etiology, speakers highlight pragmatic, data-driven approaches to cardiometabolic risk assessment, wait list frailty management, and early detection of clinical deterioration in the MELD 3.0 era. Presenters also explore electronic medical record (EMR)–based strategies to identify steatotic liver disease across the metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease spectrum, and operationalize emerging guidelines, therapies, and clinical trial pathways at scale. Together, these presentations emphasize implementation strategies adopted by high-performing centers to translate complex real-world data into measurable improvements in clinical outcomes. A focused debate on the use of glucagon-like peptide-1 receptor agonists in liver transplant candidates highlights the balance between metabolic benefit and physiologic risk.